Nageatte Ibrahim

Statistics

Publications

Citations

23.8K

H-Index

Active since

1997

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Melanoma Institute Australia

Dana-Farber Cancer Institute

The University of Sydney

Institut Gustave Roussy

Nageatte Ibrahim is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, immunotherapy, and immune checkpoint inhibitors.

ORCID

Publications per year

1997–2021

Publications

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +16

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations

Medicine, Immunology, Oncology +17

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Jacob Schachter, Antoni Ribas, Georgina V. Long et al. · The Lancet · 2017 · 1.2K citations

Medicine, Oncology, Pharmacotherapy +17

1–5 of 74